Back

Efficacy of sotagliflozin among older adults: a pooled analysis of SCORED and SOLOIST-WHF

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Closing the evidence-to-practice gap in cardiovascular pharmacotherapy: where are we still failing? Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Rahul Aggarwal

Boston (United States of America)

4 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on closing the evidence-to-practice gap in cardiovascular pharmacotherapy: where are we still failing?
Professor D. Bhatt (New York City, US)
Slides Video
Presentation thumbnail
Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis
Professor S. Mulvagh (Halifax, CA)
Abstract Slides Video
Presentation thumbnail
Undertreatment of women with lipid-lowering therapies in four European countries: results from the prospective, non-interventional MILOS Study
Professor I. Gouni-Berthold (Cologne, DE)
Abstract Slides Video
Presentation thumbnail
Effects of icosapent ethyl on risk and duration of hospitalizations and death in REDUCE-IT
Doctor D. Bhatt (New York City, US)
Abstract Slides Video

Access the full session

Session thumbnail
Closing the evidence-to-practice gap in cardiovascular pharmacotherapy: where are we still failing?
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
Late-Breaking Clinical Science: cardiometabolic medicine
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources